London: Savara on Wednesday that its experimental therapy met the main goal of a late-stage trial by improving a measure lung function In patients rare disease Becomes the reason for Difficulty breathingDue to which its shares increased by 31 percent.
This therapy is being developed to treat patients Autoimmune pulmonary alveolar proteinosis (APAP) can cause breathing problems, lung scarring, and may even require a lung transplant.
The disease is estimated to affect fewer than 5,000 people in the United States, according to government data.
Savara breathing therapy, Molgramstimhelped improve measures of lung capacity, which tracks the lungs’ ability to move gas from inhaled air into red blood cells in the blood capillaries in the lungs, compared to placebo.
The drug’s developer said molgramostim was well tolerated and the frequency of adverse events was generally similar across the different treatment groups.
Savara plans to submit a marketing application for this therapy in the first half of 2025.
(Reporting by Pratik Jain in Bengaluru; Editing by Tassim Zahid and Devika Shyamnath)
savaras-rare-lung-disease-therapy-meets-main-goal-in-late-stage-study-et-healthworld-pharma
